Thelansis’s “Alport Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Alport syndrome is an inherited collagen IV disorder caused by pathogenic variants in COL4A3, COL4A4 or COL4A5, which impair basement membranes in the kidneys, inner ear and eyes. Persistent haematuria is an early sign; proteinuria and progressive chronic kidney disease may follow. Sensorineural hearing loss and ocular abnormalities, including anterior lenticonus, occur in some patients. Disease severity varies by genetic subtype. Early renin–angiotensin system blockade is the cornerstone of kidney-protective care; SGLT2 inhibitors may be added for adults with proteinuria and chronic kidney disease. Advanced disease may require dialysis or kidney transplantation. There is no approved gene-replacement therapy. Clinical research is evaluating endothelin-pathway agents, FXR agonists, antifibrotic and podocyte-targeted treatments, with several candidates in Phase II or III trials. These approaches aim to slow renal decline, but their long-term clinical benefit remains under investigation.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Alport Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Alport Syndrome – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.